# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth Barrett Browning (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI026-SYN
- Date: 2026-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clementine Haverford-Asante, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review, seen the same morning by pulmonology with CT of the chest and spirometry. **S**

## History of present illness

Ms. Barrett Browning returns one week after her first visit and was seen this morning by Dr. Ellesmere-Park of pulmonology, who reviewed her CT and spirometry. Her three sputum samples were negative for acid-fast bacilli on smear and by nucleic acid amplification, her interferon-gamma release assay and HIV test were negative, and the routine culture grew Haemophilus influenzae. She has worn a mask with visitors and is relieved to hear that tuberculosis is very unlikely. Her cough and sputum are unchanged, about four tablespoons a day, and she saw one thin streak of blood three days ago. She takes morphine solution 5 mL twice daily as before and has used no extra. She has booked her first grief session for this week. She started vitamin D. **S**

| Element | Detail |
|---|---|
| Results since last visit | Three smears and NAAT negative; IGRA negative; HIV negative; sputum culture Haemophilus influenzae, beta-lactamase negative |
| Symptoms | Unchanged cough with four tablespoons of sputum a day; one streak of blood three days ago |
| Testing today | CT of the chest with contrast; spirometry before and after bronchodilator; immunoglobulins, total IgE and Aspergillus IgE |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or night sweats |
| Respiratory | Positive | Daily productive cough; one streak of blood; breathless on one flight of stairs |
| Cardiovascular | Positive | Palpitations at night now and then; no chest pain |
| Psychiatric | Positive | Mood heavy; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued) **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 **S**
- Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 100/64 mmHg; pulse 92 bpm; respirations 18/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 41.6 kg; BMI 16.9 kg/m². All vital signs are synthetic.

FEV1 after bronchodilator: 2.02 L (low); FEV1 percent predicted after bronchodilator: 74% (low); FVC after bronchodilator: 2.93 L; FEV1/FVC after bronchodilator: 0.69 (low); IgG: 1180 mg/dL; IgA: 236 mg/dL; IgM: 142 mg/dL; Total IgE: 38 [IU]/mL; Aspergillus fumigatus specific IgE: 0.08 k[IU]/L. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Thin, alert; weight 41.6 kg; oxygen saturation 96% on room air |
| Respiratory | Coarse crackles at the left base and left mid-zone that shift with coughing; no wheeze; no clubbing |
| Neurological | Not drowsy; pupils normal size |
| Psychiatric | Tearful once; engaged; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bronchiectasis, left lower lobe and lingula** (J47.9). The CT shows cylindrical bronchiectasis of the left lower lobe and lingula with bronchial wall thickening and mucus plugging, and no cavity, nodule, mass, or anomalous artery from the aorta, so there is no sequestration. Spirometry shows mild airflow obstruction (FEV1 2.02 L, 74% predicted; FEV1/FVC 0.69). Immunoglobulins are normal and Aspergillus-specific IgE is negative, so antibody deficiency and allergic bronchopulmonary aspergillosis are excluded; the most likely cause is a severe infection years ago. Tuberculosis is very unlikely with three negative smears, a negative NAAT and a negative IGRA; the cultures, including for nontuberculous mycobacteria, will be final in six to eight weeks. Bronchiectasis Severity Index 3 (mild). Dr. Ellesmere-Park and I agree the plan. **S**
   - Airway clearance twice daily with the active cycle of breathing and an oscillating PEP device, taught by the respiratory physiotherapist this week.
   - Home exercise program.
   - Written exacerbation plan with amoxicillin 500 mg three times daily for 14 days.
   - Influenza and pneumococcal vaccines to be given.
   - Mask no longer needed.
2. **Long-term opioid therapy** (Z79.891). Unchanged at 10 mg twice daily; no sedation. Dr. Ellesmere-Park notes that morphine damps the cough she needs to clear sputum, which is one reason to reduce slowly if she wishes, but there is no reason to change it urgently. **S**
   - Continue morphine solution 5 mL twice daily.
   - Naloxone at home.
3. **Prolonged grief disorder** (F43.81). First grief therapy session this week. No suicidal ideation; safety plan in place. **S**
   - Grief therapy weekly.
   - PHQ-9 at four weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tuberculosis: acid-fast smear, nucleic acid amplification and culture on three sputum samples; interferon-gamma release assay | Once, at diagnosis | Completed today | Three sputum smears and NAAT negative; IGRA negative; HIV negative: tuberculosis very unlikely; masking stopped |
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Ordered | Cultures from the three samples in progress |
| Imaging | CT of the chest | Once, to confirm the diagnosis | Completed today | Cylindrical bronchiectasis of the left lower lobe and lingula; no cavity, nodule, mass or sequestration |
| Laboratory | Cause of bronchiectasis: blood count, IgG, IgA and IgM, total IgE and Aspergillus-specific IgE | Once, at diagnosis; cystic fibrosis, ciliary and connective tissue tests only if the history suggests them | Completed today | Blood count normal at the first visit; IgG 1180, IgA 236, IgM 142 mg/dL; total IgE 38 IU/mL; Aspergillus IgE 0.08 kU/L: no immune deficiency or allergic aspergillosis; no features suggesting cystic fibrosis, a ciliary disorder or connective tissue disease |
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | First-visit culture: Haemophilus influenzae, beta-lactamase negative; no Pseudomonas |
| Imaging | Spirometry and Bronchiectasis Severity Index | At diagnosis, then yearly | Completed today | FEV1 2.02 L (74% predicted), FVC 2.93 L, FEV1/FVC 0.69 after bronchodilator; Bronchiectasis Severity Index 3, mild |
| Self-management | Airway clearance technique and exercise | Every visit | Ordered | Physiotherapy teaching session booked this week |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | About two winter chest infections a year by her account; written plan and rescue antibiotic given; long-term macrolide not indicated |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | One streak three days ago; emergency rules repeated |
| Self-management | Influenza and pneumococcal vaccines | Influenza yearly; pneumococcal once | Due | Pneumococcal vaccine at the next preventive visit; influenza in the autumn |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; cough suppression discussed; no change |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Two naloxone devices at home; no sedatives |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Up to date | 12 one week ago; next at four weeks |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; locked box in use |
| Referral | Pulmonology review | At diagnosis, then as advised | Completed today | Seen by Dr. Ellesmere-Park this morning |

## Goal progress

- Tuberculosis excluded and a diagnosis for the cough within two weeks. Outcome by 2026-03-23: Smears, NAAT and IGRA negative within a week; bronchiectasis diagnosed by CT at one week. **S**
- Airway clearance twice daily, with less sputum and no blood in it, by three months. In progress; target 2026-06-15. **S**
- Safe opioid therapy: naloxone at home, no overdose or sedation, and any dose change only by her choice. In progress; target 2026-10-19. **S**
- Response of grief and depressive symptoms (PHQ-9 down by at least half) by six months. In progress; target 2026-10-19. **S**
- Weight up toward a BMI of 18.5 (45.6 kg) by seven months. In progress; target 2026-10-19. **S**
- Vitamin D above 30 ng/mL by twelve weeks. In progress; target 2026-06-15. **S**

## Guideline basis

- British Thoracic Society Guideline for Bronchiectasis in Adults (2019), British Thoracic Society (Thorax 2019;74 Suppl 1:1-69)
- European Respiratory Society guidelines for the management of adult bronchiectasis (2017), European Respiratory Society (Eur Respir J 2017;50(3):1700629)
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), ATS, IDSA and CDC (Clin Infect Dis 2017;64(2):111-115)
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020), ATS, ERS, ESCMID and IDSA (Clin Infect Dis 2020;71(4):e1-e36)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026), Aether Forge

## Follow-up

- Four-week review with the mycobacterial culture progress, sputum culture, DXA, PHQ-9 and the opioid plan. Emergency care for more than a few teaspoons of blood. **S**
- Next scheduled visit 2026-04-20: four-week review: mycobacterial cultures, airway clearance, bone density, grief therapy, and her choice about the opioid dose. **S**
